European Pharmaceutical ReviewProposed guidelines for handling CAR T cell side effectsEuropean Pharmaceutical ReviewImmune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new… Continue reading
The Global Health News (press release) (blog) |
Stem Cells Market to reach US$270.5 bn by 2025, globally: Transparency Market Research
GlobeNewswire (press release) Albany – NY, Sept. 20, 2017 (GLOBE NEWSWIRE) — “The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells … ImStem, UConn Obtain US Patent for Mesenchymal Stem Cell Technology to Treat MS, Other DiseasesMultiple Sclerosis News Today Defining the Future of the Stem Cell Market and Exclusive Interviews with Stem Cell Industry Executives in 2017 ReportMedgadget (blog) “Stem Cell Therapy: A Rising Tide – How Stem Cells are Disrupting Medicine and Transforming Lives” – A New Book by …PR Web (press release) Baystreet.ca –The Global Health News (press release) (blog) –Business Wire (press release) all 23 news articles » |
BioPharma-Reporter.com |
Stem Cells Market to reach US$270.5 bn by 2025, globally: Transparency Market Research
GlobeNewswire (press release) Albany – NY, Sept. 20, 2017 (GLOBE NEWSWIRE) — “The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells … US FDA stem cell enforcement challenged by state legislationBioPharma-Reporter.com International Stem Cell Corporation to Move Forward with Traumatic Brain Injury Phase II Clinical TrialNasdaq Embryonic Stem Cell Research Still Hasn’t Cured a Single PatientLifeNews.com Medgadget (blog) –PR Web (press release) –Baystreet.ca all 27 news articles » |
BioPharma-Reporter.com |
Stem Cells Market to reach US$270.5 bn by 2025, globally: Transparency Market Research
GlobeNewswire (press release) Albany – NY, Sept. 20, 2017 (GLOBE NEWSWIRE) — “The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells … US FDA stem cell enforcement challenged by state legislationBioPharma-Reporter.com International Stem Cell Corporation to Move Forward with Traumatic Brain Injury Phase II Clinical TrialNasdaq Embryonic Stem Cell Research Still Hasn’t Cured a Single PatientLifeNews.com Medgadget (blog) –PR Web (press release) –Baystreet.ca all 27 news articles » |
GeekWire |
Juno Therapeutics’ giant new Seattle HQ is designed to destroy cancer
GeekWire It’s an exciting time to be working in CAR T immunotherapy, the kind of treatments that Juno is working on. The approach involves genetically engineering T cells in a patient’s immune system so that they seek out and destroy cancer cells. The … |
OncLive |
CAR T-Cell Therapy Active in High-Risk, Refractory CLL
OncLive “In high-risk CLL patients, CD19 CAR T cells of defined composition can be administered with an acceptable early toxicity profile,” said Cameron Turtle, MBBS, PhD, an attending physician at the Fred Hutchinson Bone Marrow Transplant Program and … |